医学
恩替卡韦
肝硬化
内科学
生活质量(医疗保健)
肝病学
失代偿
胃肠病学
HBeAg
可视模拟标度
抗病毒治疗
结直肠外科
随机对照试验
物理疗法
腹部外科
乙型肝炎病毒
乙型肝炎表面抗原
慢性肝炎
拉米夫定
免疫学
病毒
护理部
作者
Xiaoning Wu,Jia Hong,Jialing Zhou,Yameng Sun,Lei Li,Wen Xie,Hulin Piao,Xiaoyuan Xu,Wei Jiang,Bo Feng,Yongpeng Chen,Ming-Yi Xu,Jun Cheng,Tongtong Meng,Bingqiong Wang,Shuyan Chen,Yuanyuan Kong,Xiaojuan Ou,Hong You,Jidong Jia
标识
DOI:10.1007/s12072-021-10240-4
摘要
Antiviral therapy is effective in decreasing disease progression in HBV cirrhosis. However, the long-term effect of antiviral therapy on health-related quality of life (HRQoL) in patients with compensated HBV cirrhosis is unknown.The patients with compensated HBV cirrhosis enrolled in a randomized controlled trial of entecavir-based therapy were recruited in the present study, if they had HRQoL score at 5-year follow-up or who developed liver-related events (LRE) during follow-up were included. HRQoL was measured with 36-Item Short-Form Health Survey (SF-36) and EuroQol-5D (EQ-5D) at baseline and yearly during follow-up. LRE was defined as the development of decompensation, HCC, or death.A total of 161 patients were included in the present study, with a median age of 48.0 (41.0, 53.0) years, 77.6% being male and 37.2% being HBeAg-positive. During 5 years, 45 patients developed LRE. All eight dimensions of SF-36 were significantly improved after 5 years of antiviral therapy (all p < 0.001), with all dimensions improved more than five points except for physical functioning. Proportion of patients reporting no problems in all five dimensions in EQ-5D increased from 57.8 to 72.0%; visual analogue scale (VAS) and utility index (UI) increased significantly (VAS 79.8 ± 16.4 to 84.4 ± 13.2, UI 0.91 ± 0.13 to 0.95 ± 0.10, both p < 0.001). HRQoL improved or kept stable in the majority of patients who had LRE during follow-up, even stratified by Baveno VI criteria for clinically significant portal hypertension.After 5 years of ETV treatment, HRQoL significantly improved in patients with compensated HBV cirrhosis. (NCT01943617, NCT02849132).
科研通智能强力驱动
Strongly Powered by AbleSci AI